港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

483.155

-13.603-2.74%

漲家數：7

跌家數：23

平家數：3

市盈率：- -

高：496.758

開：496.758

低：480.328

收：496.758

成交量：1.15億

成交額：26.12億

市值：3,069.30億

流通市值：2,732.98億

資料載入中...

港股異動 | 歌禮制藥-B(01672.HK)早盤漲近5% 公司啓動ASC36口服片美國I期肥胖症研究

星必妥獲批填補PSVT院外「應急自救」空白，雲頂新耀3.0增長邏輯漸清晰

每日经济新闻

港股公告掘金 | 錦欣生殖：擬進一步發展一個主要聚焦女性健康的轉化醫學平台

撥康視雲製藥有限公司在香港暫停交易。

和鉑醫藥：BD進入「複利時刻」

先健科技(01302.HK)：LantvalTM主動脈瓣膜置換系統進入創新醫療器械特別審查程序

和鉑醫藥-B旗下Solstice Oncology啓動2.25億美元A輪融資

多家藥企處置資產反哺主業

李氏大藥廠(00950)與1cBio訂立獨家許可協議以在中國內地等地開發、生產及商業化OC-3

同源康醫藥-B(02410.HK)獲董事長、執行董事兼總裁吳豫生增持35萬股

特朗普打出中期選舉組合拳：強推減税與「MAHA運動」，醫藥與加工食品板塊首當其衝

對話復宏漢霖朱儁：體系出海要拿「長線收益」，2030年創新藥收入將反超生物類似藥

雲頂新耀(01952)與海森訂立戰略合作框架協議

雲頂新耀(01952.HK)與海森訂立戰略合作框架協議

勁方醫藥-B(02595)9月9日斥資196.08萬港元回購7.5萬股

康寧傑瑞製藥-B(09966)9月9日斥資98.97萬港元回購11.8萬股

和鉑醫藥-B(02142)：合作伙伴Solstice Oncology完成2.25億美元A輪融資並正式啓動運營

和鉑醫藥合作方Solstice Oncology完成2.25億美元A輪融資，推進新輔助腫瘤免疫療法Porustobart

和鉑醫藥宣佈其合作伙伴Solstice Oncology完成2.25億美元A輪融資，加速推進新輔助腫瘤免疫療法普魯蘇拜單抗

歸創通橋(02190.HK)9月9日耗資約112.29萬港元回購5.35萬股

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BK1574/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":483.15506,"timestamp":1789114133774,"preClose":496.75812,"halted":0,"volume":115323363,"delay":0,"changeRate":-0.027384,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-13.603058,"latestTime":"09-11 16:00:00","open":496.75812,"high":496.75812,"low":480.32812,"amount":2611810568,"amplitude":0.033074,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"pbRate":3.606253,"peRate":160.422718,"turnoverRate":0.004215,"increases":6,"decrements":25,"flats":1,"marketCap":306930068880,"floatMarketCap":273297591592},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":496.75812,"amplitude":0.033074,"preClose":496.75812,"low":480.32812,"pbRate":"3.606253","latestPrice":483.15506,"volume":115323363,"delay":0,"open":496.75812,"prevYearClose":556.26263,"prevWeekClose":532.025,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":532.025,"twentyDayClose":518.327,"sixtyDayClose":434.471,"secType":"PLATE","market":"HK","turnoverRate":0.004215,"peRate":160.422718,"marketCap":306930068880,"floatMarketCap":273297591592,"timestamp":1789114133774,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":7,"down":23,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666559944","title":"港股異動 | 歌禮制藥-B(01672.HK)早盤漲近5% 公司啓動ASC36口服片美國I期肥胖症研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2666559944","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666559944?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 09:27","pubTimestamp":1789003653,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","01477","BK1515","BK1161","BK1191","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666559836","title":"星必妥獲批填補PSVT院外「應急自救」空白，雲頂新耀3.0增長邏輯漸清晰","url":"https://stock-news.laohu8.com/highlight/detail?id=2666559836","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666559836?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 09:00","pubTimestamp":1789002017,"startTime":"0","endTime":"0","summary":"云顶新耀在心血管领域，拿下了一张关键“王牌”。9月3日，云顶新耀宣布，中国国家药品监督管理局（NMPA）已批准星必妥?（艾曲帕米鼻喷雾剂）的新药上市许可申请（NDA），用于治疗成人阵发性室上性心动过速（PSVT）急性症状发作，转复为窦性心律。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609103870101240.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609103870101240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","01952","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666556236","title":"港股公告掘金 | 錦欣生殖：擬進一步發展一個主要聚焦女性健康的轉化醫學平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2666556236","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666556236?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 08:52","pubTimestamp":1789001570,"startTime":"0","endTime":"0","summary":"重大事项：赛晶科技(00580)拟参设合资公司投资高性能TPU AI芯片相关业务安井食品(02648)：对外投资暨设立印度尼西亚合资公司并签署股东协议福田实业(00420)附属拟2794.5万美元收购一家越南公司81%出资份额和铂医药-B(02142)：合作伙伴Solstice Oncology完成2.25亿美元A轮融资并正式启动运营中国能源建设(03996)：子公司中标陕投赵石畔电厂二期2×10","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494215.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1219","00950","BK1191","01951","BK4585","BK1574","02142","BK1189","BK1161","BK1597","VXUS","00580","FHCO","KCAI","BK1583","BK1116","06681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666555782","title":"撥康視雲製藥有限公司在香港暫停交易。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666555782","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666555782?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 08:24","pubTimestamp":1788999844,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","BK1574","01477","02592","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666295555","title":"和鉑醫藥：BD進入「複利時刻」","url":"https://stock-news.laohu8.com/highlight/detail?id=2666295555","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666295555?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 08:19","pubTimestamp":1788999594,"startTime":"0","endTime":"0","summary":"中国创新药BD出海正在经历一场质变。","market":"hk","thumbnail":"https://img7.gelonghui.com/column/2/110.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/110.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6581147","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1574","BK1161","02142","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666555596","title":"先健科技(01302.HK)：LantvalTM主動脈瓣膜置換系統進入創新醫療器械特別審查程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2666555596","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666555596?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 08:06","pubTimestamp":1788998762,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09996","01302","BK1100","BK1583","BK1574","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132556829","title":"和鉑醫藥-B旗下Solstice Oncology啓動2.25億美元A輪融資","url":"https://stock-news.laohu8.com/highlight/detail?id=1132556829","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132556829?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 23:21","pubTimestamp":1788967293,"startTime":"0","endTime":"0","summary":"9月9日，路透社消息——和铂医药-B（2142.HK）今日公告，其旗下Solstice Oncology正式启动A轮融资，规模高达2.25亿美元。此举标志着该公司在肿瘤治疗领域的战略布局迈出关键一步。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02142","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666539022","title":"多家藥企處置資產反哺主業","url":"https://stock-news.laohu8.com/highlight/detail?id=2666539022","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666539022?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 22:59","pubTimestamp":1788965940,"startTime":"0","endTime":"0","summary":"除此之外，今年以来，多瑞医药先后将厦门瑞蒂莲69%股权转让给关联方西藏嘉康时代科技发展有限公司，属于首批处置的非核心资产；为了剥离低效制剂相关业务，多瑞医药还将湖北海瑞迪100%股权全部转让给关联方西藏嘉康。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hyyj/2026-09-09/doc-inirfytq8374634.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1574","FOSL","09939","BK1191","BK1593","BK4202","02196","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666399605","title":"李氏大藥廠(00950)與1cBio訂立獨家許可協議以在中國內地等地開發、生產及商業化OC-3","url":"https://stock-news.laohu8.com/highlight/detail?id=2666399605","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666399605?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 22:38","pubTimestamp":1788964683,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂 发布公告，集团全资附属公司李氏大药厂(香港)有限公司与1cBio, Inc.订立独家许可协议，以在中国内地、香港、澳门、台湾及东南亚若干其他国家开发、生产及商业化OC-3。根据该协议，李氏香港将负责为OC-3在该地区取得监管批准所需的GLP安全性研究及生产活动，该协议亦包括订约双方之间的药物供应生产安排。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494142.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00950","06622","BK1574","BK1583","BK1191","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666392539","title":"同源康醫藥-B(02410.HK)獲董事長、執行董事兼總裁吳豫生增持35萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666392539","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666392539?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 22:17","pubTimestamp":1788963422,"startTime":"0","endTime":"0","summary":"格隆汇9月9日丨根据联交所最新权益披露资料显示，2026年9月8日，同源康医药-B(02410.HK)获董事长、执行董事兼总裁吴豫生在场内以每股均价3.4626港元增持35万股，涉资约121.2万港元。\n\n　　增持后，吴豫生最新持股数目为123,816,000股，持股比例由32.48%上升至32.57%。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/09/20260909128261.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/09/20260909128261.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260909/32365336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","BK1161","159938","09939","BK1515","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666536659","title":"特朗普打出中期選舉組合拳：強推減税與「MAHA運動」，醫藥與加工食品板塊首當其衝","url":"https://stock-news.laohu8.com/highlight/detail?id=2666536659","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666536659?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 21:35","pubTimestamp":1788960918,"startTime":"0","endTime":"0","summary":"智通财经APP注意到，美国总统特朗普在11月中期选举前的助选热情不高、花钱也相当节省。白宫一年来一直承诺特朗普会外出为候选人助选，但实际成果寥寥。一位讨论特朗普周三晚达拉斯讲话的共和党官员表示，民主党已经在针对总统及其政策开展竞选，因此以全国性策略应对中期选举是合理的。鉴于选情，一些共和党人表示，特朗普主打基本盘是合理的。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494110.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1515","159151","159938","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666356195","title":"對話復宏漢霖朱儁：體系出海要拿「長線收益」，2030年創新藥收入將反超生物類似藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2666356195","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666356195?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 21:04","pubTimestamp":1788959040,"startTime":"0","endTime":"0","summary":"新浪科技讯 9月9日晚间消息，在2026亚布力论坛夏季年会期间，在与新浪科技的对话中，复宏汉霖执行董事、首席执行官朱俊博士系统阐释了公司“体系出海”战略的底层逻辑。另一种是复宏汉霖坚持的“体系出海”，最终目的是拿到“长线收益”。营收方面，朱俊表示公司上半年实现营收35.88亿元，其中海外收入占比达19%，海外产品销售收入同比大幅提升159.4%至1.05亿元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-09/doc-inirfumn8933987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000320264.USD","IBBQ","HK0000306685.HKD","LNGR","HK0000306701.USD","LU2322448957.HKD","LU2272731865.HKD","159992","LU1992135472.HKD","HK0000320223.HKD","PPH","BK4588","IBB","BK1574","BK1161","LU2473716301.USD","MEDX","LU2272731782.SGD","XPH","BK4585","LU1992135399.USD","HK0000165453.HKD","IE00B5TLWC47.USD","06978","LU2322448791.USD","LU2272731600.USD","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538266","title":"雲頂新耀(01952)與海森訂立戰略合作框架協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538266","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538266?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 20:13","pubTimestamp":1788956015,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀 发布公告，于2026年9月9日，该附属公司与海森订立战略合作框架协议，订约双方同意就产品在中国的供应、分销及相关制造与商业化建立框架。董事会认为，战略合作框架协议将使本集团能够进一步利用其供应链、制造及商业化基础设施，并扩大其收入基础，同时深化与海森的战略合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","01952","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538265","title":"雲頂新耀(01952.HK)與海森訂立戰略合作框架協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538265","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538265?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 20:13","pubTimestamp":1788956015,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1574","BK1583","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538468","title":"勁方醫藥-B(02595)9月9日斥資196.08萬港元回購7.5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538468","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538468?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 20:11","pubTimestamp":1788955898,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2026年9月9日，该公司斥资196.08万港元回购7.5万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","02595","BK1515","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666690538","title":"康寧傑瑞製藥-B(09966)9月9日斥資98.97萬港元回購11.8萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666690538","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666690538?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:57","pubTimestamp":1788955030,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2026年9月9日斥资98.97万港元回购11.8万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260909/32365182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","09966","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587444","title":"和鉑醫藥-B(02142)：合作伙伴Solstice Oncology完成2.25億美元A輪融資並正式啓動運營","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587444","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587444?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:13","pubTimestamp":1788952398,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B 发布公告，公司的合作伙伴公司Solstice Oncology 已完成2.25亿美元的A轮融资并正式启动运营。Solstice是一家临床阶段的肿瘤免疫公司，致力于在新辅助治疗阶段更早地干预癌症。MSS型是结肠癌中占比最大的亚型，迄今为止该患者群体仍未能从免疫治疗中获益。该2期临床试验预计将于 2026年第四季度初启动患者入组，并预期将于2027年下半年取得该研究数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B(02142)：合作伙伴Solstice Oncology完成2.25亿美元A轮融资并正式启动运营","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02142","BK1574","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136108597","title":"和鉑醫藥合作方Solstice Oncology完成2.25億美元A輪融資，推進新輔助腫瘤免疫療法Porustobart","url":"https://stock-news.laohu8.com/highlight/detail?id=1136108597","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136108597?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:13","pubTimestamp":1788952393,"startTime":"0","endTime":"0","summary":"和铂医药的合作伙伴Solstice Oncology宣布，已成功完成2.25亿美元的A轮融资。这笔资金将用于加速其核心候选药物Porustobart的临床开发，该药物定位为新辅助免疫肿瘤学疗法。Solstice Oncology表示，所筹资金将重点投向Porustobart的后续临床试验，旨在探索该药物在早期肿瘤治疗中的应用潜力，以期在手术前缩小肿瘤、改善患者预后。Porustobart作为一种创新免疫疗法，其设计初衷是在标准手术干预前调动患者自身免疫系统对抗肿瘤。Solstice Oncology的此番布局，有望为这一赛道注入新的活力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","02142","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666539369","title":"和鉑醫藥宣佈其合作伙伴Solstice Oncology完成2.25億美元A輪融資，加速推進新輔助腫瘤免疫療法普魯蘇拜單抗","url":"https://stock-news.laohu8.com/highlight/detail?id=2666539369","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666539369?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:12","pubTimestamp":1788952320,"startTime":"0","endTime":"0","summary":"普鲁苏拜单抗治疗结肠癌的2期试验将于2026年第四季度初启动患者入组。和铂医药创始人、董事长兼首席执行官王劲松博士表示：\"我们非常高兴看到Solstice Oncology在顶级投资者的有力支持下成功启动运营，并将普鲁苏拜单抗推进至新辅助治疗领域。关于Solstice Oncology Solstice Oncology是一家临床阶段的肿瘤免疫公司，专注于新辅助治疗领域。Solstice成立于2026年2月，核心团队在肿瘤领域拥有数十年成功研发和推进免疫治疗药物的丰富经验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5043403_ZH43403_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5043403_ZH43403_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["CANC","BK1161","BK1583","02142","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666821805","title":"歸創通橋(02190.HK)9月9日耗資約112.29萬港元回購5.35萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666821805","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666821805?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:45","pubTimestamp":1788950746,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1583","02190","BK1587","BK1100"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":4,"totalSize":344,"code":"91000000","status":"200"}]}}